From Alzheimer’s to Zebrafish: Eclectic Science and Regulatory Stories 164
6. “Indian Polycap Study: Effects of a Polypill (Polycap) on risk factors in middle-aged individuals without
cardiovascular disease: a phase II, double blind randomized trial.” Lancet. 2009 373(9672):1341–51.
7. Op cit 5.
8. Reddy KS. “The preventive Polypill—much promise, insufficient evidence.” NEJM. 2007 356(3):212.
9. Op cit 3.
10. Smith R. “Take forward the Polypill idea, concludes expert committee.” BMJ. 2005 330:8.
11. “Polypill halves predicted heart disease and stroke risk, study suggests.” Science Daily. 25 May 2011.
12. Op cit 5.
13. Ibid.
14. Smith R. “The Polypill is about demedicalisation not medicalisation.” BMJ Group Blogs. 1 May 2009.
15. Franco OH, et al. “The Polymeal: a more natural, safer and probably tastier (than the Polypill) strategy to
reduce cardiovascular disease by more than 75%.” BMJ. 2004 329:1447–50.
Published in Regulatory Focus, December 2011. Copyright © 2011 Regulatory Affairs Professionals Society.
6. “Indian Polycap Study: Effects of a Polypill (Polycap) on risk factors in middle-aged individuals without
cardiovascular disease: a phase II, double blind randomized trial.” Lancet. 2009 373(9672):1341–51.
7. Op cit 5.
8. Reddy KS. “The preventive Polypill—much promise, insufficient evidence.” NEJM. 2007 356(3):212.
9. Op cit 3.
10. Smith R. “Take forward the Polypill idea, concludes expert committee.” BMJ. 2005 330:8.
11. “Polypill halves predicted heart disease and stroke risk, study suggests.” Science Daily. 25 May 2011.
12. Op cit 5.
13. Ibid.
14. Smith R. “The Polypill is about demedicalisation not medicalisation.” BMJ Group Blogs. 1 May 2009.
15. Franco OH, et al. “The Polymeal: a more natural, safer and probably tastier (than the Polypill) strategy to
reduce cardiovascular disease by more than 75%.” BMJ. 2004 329:1447–50.
Published in Regulatory Focus, December 2011. Copyright © 2011 Regulatory Affairs Professionals Society.